Enhanced synthesis of albumin and fibrinogen at high altitude.

The acute effects of active and passive ascent to high altitude on plasma volume (PV) and rates of synthesis of albumin and fibrinogen have been examined. Measurements were made in two groups of healthy volunteers, initially at low altitude (550 m) and again on the day after ascent to high altitude (4,559 m). One group ascended by helicopter (air group, n = 8), whereas the other group climbed (foot group, n = 9), so that the separate contribution of physical exertion to the response could be delineated. PV was measured by dilution of (125)I-labeled albumin, whereas synthesis rates of albumin and fibrinogen were determined from the incorporation of isotope into protein after injection of [ring-(2)H(5)]phenylalanine. In the air group, there was no change in PV at high altitude, whereas, in the foot group, there was a 10% increase in PV (P < 0.01). Albumin synthesis (mg. kg(-1). day(-1)) increased by 13% in the air group (P = 0.058) and by 32% in the foot group (P < 0.001). Fibrinogen synthesis (mg. kg(-1). day(-1)) increased by 40% in the air group (P = 0.068) and by 100% in the foot group (P < 0.001). Hypoxia and alkalosis at high altitude did not differ between the groups. Plasma interleukin-6 was increased modestly in both groups but C-reactive protein was not changed in either group. It is concluded that increases in PV and plasma protein synthesis at high altitude result mainly from the physical exercise associated with climbing. However, a small stimulation of albumin and fibrinogen synthesis may be attributable to hypobaric hypoxia alone.

Quantitation and confirmation of the diazolo- and triazolobenzodiazepines in human urine by gas chromatography/mass spectrometry.

We report a reliable, rapid, sensitive, and quantitative method for the N- and O-trimethylsilyl (TMS) derivatives of the diazolo- and triazolobenzodiazepines after enzymatic incubation (2 h) and liquid-liquid extraction of 0.5-mL urine volumes. Each analyte was identified by gas chromatography/mass spectrometry through the retention time for the total ion current (TIC) and selected ion monitoring (SIM) of four ion currents. Quantitation of the diazolobenzodiazepines was obtained by the ratio of the base peak ion of the TMS analyte to that of the internal standard bromazepam in the concentration range 50-500 ng/mL (1-10 ng injected into the GC/MS). The limit of detection (LOD) at p less than 0.01 was 50 ng/mL for all the diazolobenzodiazepines. The assay was not quite as sensitive for triazolobenzodiazepines (5-20 ng injected in the GC/MS). The extraction efficiency of the assay ranged from 75 to 92% for all the analytes. The coefficient of variation (CV) for the diazolobenzodiazepines ranged from 5.4 to 9.4% for within-day runs and from 11.1 to 13.9% for between-day runs. For the triazolobenzodiazepines the values were 3.8 to 18.9% for a single day and 3.4 to 19.9% between days. The selected ion current ratio for each analyte was determined for a single day and over a one-week period. There was no statistical difference in the ratios during this time. The confirmation of diazolobenzodiazepines in urine by this method was relatively easy after screening by the immunoassay technique. Identification of triazolobenzodiazepines appeared to be more difficult by both the screening technique and the GC/EI/MS analysis.

Confirmation and quantitation of barbiturates in human urine by gas chromatography/mass spectrometry.

A sensitive, reliable, rapid quantitative method was developed for the N,N'-dimethyl derivatives of the 5,5'-disubstituted barbiturates (NNDM-barbiturates) after liquid-liquid extraction of 0.5-mL urine volumes. Each barbiturate was identified by GC/MS through the retention time for the total ion current and selected ion monitoring of four ion currents for each analyte. Quantitation was achieved through the base peak ion ratios for each NNDM-barbiturate/tolylbarbiturate (IS) over the concentration range 20-250 ng/mL (0.4 to 5 ng injected into the GC/MS). The limit of detection for all the barbiturates (p less than 0.01) was 20 ng/mL (0.4 ng total). The extraction efficiency ranged from 75 to 84% for all the barbiturates. The coefficient of variation of the barbiturates for the within-day run was 2.5 to 4.8% and between days was 6.7 to 8.6%. The percentage abundances of the ion current ratios for each NNDM-barbiturate was determined and found to be fully stable over a one-week period. This method is currently in routine use in our laboratory for the GC/MS confirmation of presumably positive barbiturate urine samples.

Rendering the "poppy-seed defense" defenseless: identification of 6-monoacetylmorphine in urine by gas chromatography/mass spectroscopy.

We report a sensitive, rapid, quantitative gas chromatographic/mass spectroscopic method for measuring the 6-monoacetylmorphine (6-MAM) metabolite of heroin in 0.5 mL of human urine. After a simple liquid-liquid extraction and derivatization, the trimethylsilyl derivative of 6-MAM is identified from its retention time (total ion current) and by selected ion monitoring. The limit of detection was 10 micrograms/L, corresponding to 0.2 ng of trimethylsilyl-6-MAM injected into the gas chromatograph/mass spectrometer. The presence of 6-MAM in urine is indicative of heroin. 6-MAM is not present in poppy seeds or in urine after the ingestion of products containing poppy seed.

Confirmation and quantitation of cocaine, benzoylecgonine, ecgonine methyl ester in human urine by GC/MS.

A rapid, sensitive, reliable quantitative GC/MS method using 0.2 mL of urine was developed for the confirmation of cocaine use. After a simple organic solvent extraction and derivatization with pentafluoropropionic anhydride, cocaine, benzoylecgonine, and ecgonine methyl ester were identified by GC/MS through the retention time for the total ion current and selected ion monitoring (SIM) for each analyte. Quantitation was achieved by obtaining the calibration curves for the molecular ion ratios of the analyte/ketamine (IS) over a range of 12.5-250 ng/mL (0.1-2 ng total). The extraction efficiency for these analytes ranged from 70 to 82%. The sensitivity limit of detection for each analyte was 12.5 ng/mL (0.1 ng) at p less than 0.01. Intra- and interday precision for these analytes ranged between 14.7 and 29.5% CV. This method is in routine use in our laboratory for the GC/MS confirmation of enzyme immunoassay cocaine-positive urine samples.

Confirmation of marijuana, cocaine, morphine, codeine, amphetamine, methamphetamine, phencyclidine by GC/MS in urine following immunoassay screening.

Rapid, reliable, sensitive, qualitative, and quantitative methods using small urine volumes (0.2-0.5 mL) were developed primarily for confirmation of marijuana, cocaine, benzoylecgonine, ecgonine methyl ester, morphine, codeine, amphetamine, methamphetamine, and phencyclidine. Using capillary gas chromatography/mass spectrometry (GC/MS) and selected ion monitoring (SIM), mass spectra were obtained for each analyte. Samples were prepared by hydrolysis where applicable, organic solvent extraction, and derivatization where necessary. Confirmation was achieved by comparing abundance of major ions and retention time of the total ion current (TIC) of an analyte with those of the appropriate analytical standard. Quantitation was achieved and calibration curves derived by obtaining the molecular ion ratios of that analyte/internal standard (IS) over a concentration range of 10-300 ng/mL (0.16-4.0 ng total injected into GC/MS). The overall extraction efficiency for these analytes ranged from 53% to 96%. Statistically significant cut-off values (p less than 0.01) were obtained for each analyte. The slope, y-intercept, and coefficient of determination (r2) were calculated for each analyte. All of the GC/MS methods were extensively tested against urine samples determined positive or negative by immunoassay (IA) and are now used in our laboratory.

delta 9-Tetrahydrocannabinol: EEG changes, bradycardia and hypothermia in the rhesus monkey.

Administration of delta 9-tetrahydrocannabinol (THC; 0.75-4.0 mg/kg IP) to rhesus monkeys produced a biphasic pattern of high-voltage slow waves (HVSW) and fast waves (HVFW) EEG, along with behavioral depression and alertness, respectively. The HVSW phase appeared 20 to 30 min after drug injection and was uniquely characterized by spike-bursts in frontal and temporal lobes and hypothalamus, theta-waves in parietal and occipital lobes, and generalized HVSW in subcortical regions. During the HVSW phase, bradycardia and hypothermia occurred, and animals exhibited depression or sedation. After the HVSW phase lasting for 3-4 hr, HVFW predominated in overall EEGs with marked decrease in neocortical spike-bursts. Bradycardia and hypothermia occurred simultaneously 20 to 30 min after drug injection and reached maximal levels (30-40 percent decrease in heart rate, 1.5-2.0 degrees C decrease in body temperature) 2 to 3 hr after injection. The dose- and time-response relationships for bradycardia and hypothermia paralleled the HVSW phase with behavioral depression. Animals were alert and calm during recovery from bradycardia and hypothermia. THC levels and disposition in blood correlated with bradycardia, hypothermia and EEGs and behavioral changes following THC administration.

The effect of ethanol on the metabolism of chronically-administered l-alpha-acetylmethadol (LAAM) in the rhesus monkey.

The metabolism of 3H-LAAM was studied in monkeys treated acutely and chronically with 2 mg/kg LAAM via intragastric catheter three times weekly. From the 15th week, 250 mg/kg ethanol every 2 hours (3g/kg/day) was also administered. This dose of ethanol did not impair the metabolism of LAAM in monkeys.